Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc.

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Immuron Limited

Abbott develops and delivers health care technologies and products. The company focuses on various sectors of health care, including diagnostics and nutrition. Self-described as a provider of life-changing solutions.

Abbott

Allarity Therapeutics is a clinical-stage precision medicine company focusing on developing therapeutics for cancer treatment. The company is advancing stenoparib, an orally available small molecule inhibitor for patients with advanced recurrent ovarian cancer, utilizing its Drug Response Predictor technology for improved patient selection.

Allarity Therapeutics

Citius Pharmaceuticals, Inc. develops innovative therapeutics for patients with critical diseases. The company focuses on advancing medical treatments for conditions such as infectious diseases and oncology. The company self-described as unlocking potential faster.

Metric
Company Name	Citius Pharmaceuticals, Inc.	Immuron Limited	Abbott	Allarity Therapeutics
Symbol	CTXR	IMC
MSH ID	COM:CITIUSPHARMA	AU:COM:IMMURON	COM:ABBOTT	COM:ALLARITY
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Medical Devices and Diagnostics	Biotechnology
Country	US	AU	US	US
Stage	Post-IPO
Employee Count	22	6	10.00K
Website	citiuspharma.com	immuron.com.au	abbott.com	allarity.com
LinkedIn				allaritytx
Founders

Metric
Market Cap	134.75M	12.38M
Enterprise Value
Monthly Web Traffic	1.01K		873.36K
Web Traffic Growth	-0.63		-0.14
Valuation
Raised Capital	3M

Metric
Revenue		3.13M
Revenue (LTM)
Revenue (NTM)
Gross Profit		2.13M
EBITDA		-6.44M
Operating Income		-5.51M
Net Income		-4.43M
EPS		-0.02
Diluted EPS		-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.69
Operating Profit Margin		-1.54
EBITDA Margin		-2.06
Net Profit Margin		-1.09
Return on Equity		-0.21
Return on Assets		-0.20
Return on Capital Employed		-0.36

COM:CITIUSPHARMA

Citius Pharmaceuticals, Inc.

Last Close

0.17

22/11 21:00

Market Cap

134.75M

Beta: -

Volume Today

15.99M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-4.51
P/B Ratio		0.87
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		7.01
EV Multiple		-3.74

Metric
Days Sales Outstanding		84.42
Days Payables Outstanding		1.76K
Days Inventory Outstanding		530.20
Operating Cycle		587.29
Cash Conversion Cycle		321.39
Asset Turnover		0.32

Metric
Operating Cash Flow		-3.55M
Free Cash Flow		-3.55M
Cash Flow to Debt
Operating Cash Flow/Sales		-0.95
Free Cash Flow Yield		-0.15

Metric
Cash & Equivalents		7.45M
Accounts Receivable
Inventory		1.01M
Goodwill
Debt to Capitalization		0.01
Debt to Assets		0.01
Current Ratio		9.20
Quick Ratio		7.79

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.13
R&D to Revenue		1.44
SG&A to Revenue		2.34